If you have vitiligo, treatment today looks very different from it did a few decades ago. Earlier approaches relied mainly on broad anti-inflammatory medicines and ultraviolet light, while newer options can target specific immune-signalling pathways involved in non-segmental vitiligo.
This progress did not come from one single breakthrough. Phototherapy, corticosteroids, calcineurin inhibitors, targeted light and, more recently, topical JAK inhibition have each expanded the options your dermatologist may discuss with you. Even with these advances, no treatment can guarantee complete or permanent repigmentation, and your response can vary according to the type, location, duration and activity of your vitiligo.
What Is Happening in Your Skin When You Have Vitiligo?
Vitiligo is a chronic condition in which an autoimmune response plays a major role in the loss of functioning melanocytes, the cells that normally produce pigment in your skin. This understanding has been important because it helped researchers identify immune pathways that could potentially be modified with treatment.
Modern treatment therefore has two broad aims: helping control ongoing disease activity and, where possible, encouraging repigmentation from surviving melanocytes or melanocyte reservoirs. Your ability to repigment varies between body sites and individuals, so controlling immune activity does not guarantee complete restoration of your previous skin colour.
Why Were Early Vitiligo Treatments So Unpredictable?
For many years, treating vitiligo could be frustrating because no single therapy worked consistently for everyone, and different areas of your body could respond very differently. This made it difficult to predict how much repigmentation you might achieve with a particular treatment.
Researchers therefore explored different medicines and forms of ultraviolet light to find ways of slowing pigment loss and encouraging repigmentation. These early approaches helped build the foundation for the more targeted treatment options available today.
How Did Light-Based Vitiligo Treatment Begin?
The history of light-based vitiligo treatment extends much further back than modern dermatology. Historical accounts describe plant preparations containing naturally occurring psoralens being combined with sunlight in ancient India and Egypt. Modern development accelerated during the twentieth century as psoralen compounds were isolated and used more systematically with ultraviolet exposure.
Modern PUVA treatment developed during the mid-twentieth century by combining a psoralen photosensitiser with controlled UVA exposure. Although PUVA later became an important treatment for vitiligo, it has largely been displaced by narrowband UVB in current UK practice because NB-UVB avoids psoralen and generally has a more favourable treatment profile.
How Did Corticosteroids Change Vitiligo Treatment?
Topical corticosteroids became an important way of suppressing local immune and inflammatory activity in vitiligo. A small 1976 study involving 20 patients provided early clinical and microscopic evidence that corticosteroid treatment could stimulate repigmentation in selected areas, although the response was far from universal.
If topical treatment is appropriate for you, your dermatologist may recommend a potent or very potent topical corticosteroid as a first-line option. Current British Association of Dermatologists guidance supports once-daily treatment for appropriate vitiligo, while your dermatologist will take extra care around sensitive areas such as the skin immediately surrounding your eyes.
What Should You Know About Steroid Treatment?
Topical corticosteroids can help treat inflammation, but prolonged or inappropriate use may cause side effects such as skin thinning. Your dermatologist will consider the steroid strength, treatment area and duration of use.
- Skin thinning: Long-term use can make treated skin thinner.
- Treatment duration: Your dermatologist considers how long you need treatment.
- Sensitive areas: Extra care is needed when treating thinner or more sensitive skin.
- Intermittent use: Corticosteroids may be used in planned treatment periods.
- Alternative treatments: Options such as topical calcineurin inhibitors may be considered.
These limitations helped encourage safer, more flexible treatment approaches. Your dermatologist can review your treatment regularly and adjust it when needed.
How Can Phototherapy Expand Your Treatment Options?
PUVA combined a psoralen medicine with UVA radiation and became an important form of modern vitiligo phototherapy. It demonstrated that controlled ultraviolet exposure could help encourage repigmentation, but treatment could be burdensome and psoralen introduced additional adverse effects and practical considerations.
If topical treatment has not given you an adequate response, or if your vitiligo is extensive or progressing, your dermatologist may discuss narrowband UVB with you. Current UK guidance generally recommends NB-UVB as the first-line form of phototherapy, while PUVA may be considered for selected adults when NB-UVB is unavailable or has not worked.
What Did the UK HI-Light Trial Show?
Combining treatments became an important area of vitiligo research because reducing local inflammation while stimulating repigmentation may offer greater benefits than either approach alone. The UK HI-Light trial studied 517 adults and children aged 5 years and over with active, limited vitiligo and found that combination treatment produced the highest rate of successful treatment after nine months.
Findings From the UK HI-Light Trial
| Treatment | Participants With Successful Treatment | Key Finding | Long-Term Consideration |
| Topical corticosteroid alone | 17% | Provided successful treatment in a smaller proportion of participants | Some responders later lost their response |
| Handheld NB-UVB alone | 22% | Performed better than corticosteroid alone | Response was not always maintained |
| Combination treatment | 27% | Produced the highest success rate and was statistically superior to corticosteroid alone | Repigmentation could still be lost after treatment stopped |
| Overall trial | 517 participants | Included adults and children aged 5 years and over with active, limited vitiligo | Demonstrated that treatment response can remain limited |
| Nine-month assessment | All treatment groups | Combination therapy showed the strongest results | Successful treatment was achieved in fewer than one-third of participants |
| Following year | Responders were followed without treatment | More than 40% of responders lost their response | Highlights the challenge of maintaining repigmentation |
What Could Combination Treatment Mean for You?
If you have active, localised vitiligo, your dermatologist may sometimes consider combining a topical corticosteroid with NB-UVB rather than using one treatment alone. In the UK HI-Light trial, combination treatment was more successful than topical corticosteroid alone, although only 27% met the study’s definition of treatment success.
For you, this means combination treatment may improve the chance of a useful response, but it still cannot guarantee repigmentation. Some people also lose part of their response after treatment stops, so longer-term expectations should be discussed before treatment begins.
When Might Tacrolimus Be Considered for You?
If facial vitiligo affects you, your dermatologist may consider tacrolimus 0.1% ointment as a non-steroid alternative to a potent or very potent topical corticosteroid. Tacrolimus is used off-label for vitiligo in the UK, but BAD guidance supports considering it for facial vitiligo and selected other areas.
A 2021 randomised controlled study involving 42 adults with facial vitiligo found that 65% of those treated with tacrolimus 0.1% achieved at least 75% repigmentation of the target lesion after 24 weeks, compared with none receiving vehicle treatment. The results support its usefulness in selected patients, but they should not be interpreted as applying to every body site or every type of vitiligo.
Can Targeted Light Treat Individual Vitiligo Patches?
If your vitiligo is localised to a small number of patches, 308-nm excimer laser or light can direct treatment more precisely towards the affected skin. This can limit unnecessary exposure of surrounding unaffected skin compared with whole-body phototherapy.
Current BAD guidance says excimer laser or light can be considered for localised vitiligo, particularly in combination with a topical calcineurin inhibitor. However, this form of treatment is not widely available through the NHS and is generally limited to centres with a specialist interest.
When Might Surgery Be Considered for Vitiligo?
Not every advance in vitiligo treatment involved medicines or light. Techniques such as blister grafting and melanocyte-containing cell suspensions were also developed to transfer functioning pigment cells into selected areas of stable vitiligo.
If your vitiligo has been stable and has not responded to other treatments, your dermatologist may discuss surgical treatment in selected circumstances. BAD guidance says cellular grafting may be considered for stable segmental or non-segmental vitiligo that continues to cause distress, although these procedures are available in only a limited number of specialist NHS centres.
Why Did Researchers Start Targeting the Immune System?
As vitiligo research became more detailed, scientists identified an important role for immune signalling involving interferon-gamma and the JAK-STAT pathway. These signals help recruit and maintain immune cells that attack melanocytes within affected skin.
This offered researchers a more precise therapeutic target. Instead of suppressing inflammation broadly, medicines could potentially interrupt a specific signalling pathway involved in maintaining the autoimmune response, helping lead to the development of topical ruxolitinib.
How Did JAK Inhibitors Change Vitiligo Treatment?
Janus kinase inhibitors became an important research focus because JAK signalling lies downstream of immune pathways involved in non-segmental vitiligo. Several JAK inhibitors have been investigated, but this does not mean that every medicine in the class is licensed or recommended for vitiligo.
Ruxolitinib cream inhibits JAK1 and JAK2 and became the first treatment specifically approved for non-segmental vitiligo with facial involvement in adults and adolescents aged 12 years and over. Its development represented a shift towards targeting a defined immune-signalling pathway rather than relying entirely on broader anti-inflammatory treatments.
What Did the Ruxolitinib Trials Show?
Two phase 3 studies, TRuE-V1 and TRuE-V2, enrolled 674 people aged 12 years or over with non-segmental vitiligo affecting no more than 10% of their total body surface area. Participants applied ruxolitinib 1.5% cream or vehicle twice daily for 24 weeks before all participants could receive ruxolitinib through week 52.
At week 24, at least 75% improvement in facial vitiligo scores was achieved by 29.8% of people receiving ruxolitinib compared with 7.4% receiving vehicle in TRuE-V1, and by 30.9% compared with 11.4% in TRuE-V2. Repigmentation continued to improve for some people with longer treatment, but these results also show that a major response is not guaranteed. For you, this means improvement may be meaningful but gradual, and a strong response cannot be predicted or guaranteed after the first few months of treatment.
When Was Ruxolitinib Authorised for Vitiligo?
The European Commission authorised Opzelura in April 2023 for non-segmental vitiligo with facial involvement in adults and adolescents aged 12 years and over. Current UK product information carries the same indication.
Authorisation was important because ruxolitinib was developed specifically around a molecular pathway involved in vitiligo rather than being an older medicine used off-label. However, regulatory authorisation and NHS funding are separate steps, which is why access in England developed later.
When Did Ruxolitinib Reach the NHS in England?
On 24 February 2026, NICE published final draft guidance recommending ruxolitinib cream for eligible people with non-segmental vitiligo. Final technology appraisal guidance, TA1140, followed on 17 March 2026.
The NHS recommendation is narrower than the medicine’s full marketing authorisation. NICE recommends ruxolitinib for people aged 12 years and over with non-segmental vitiligo involving the face only when topical first-line treatments have not worked or are unsuitable and the company provides the medicine under the agreed commercial arrangement. NICE anticipates that treatment will be prescribed, supplied and monitored in secondary care.
What Should You Know About Ruxolitinib Today?
Ruxolitinib cream should be initiated and supervised by a doctor experienced in diagnosing and treating non-segmental vitiligo. Current UK product information recommends applying a thin layer twice daily, at least eight hours apart, to depigmented areas covering no more than 10% of your body surface area. Satisfactory repigmentation may require treatment beyond 24 weeks, and stopping treatment should be considered if there is less than 25% repigmentation in treated areas at week 52.
Ruxolitinib cream is contraindicated during pregnancy and breastfeeding. Non-melanoma skin cancers have been reported in people using topical ruxolitinib, although a causal relationship has not been established, so periodic skin examination is recommended, particularly if you have relevant risk factors. You should use the medicine as prescribed and should not independently combine it with other treatments on the same areas.
Vitiligo Treatment Is Not Only About Repigmentation
Treatment does not have to mean actively trying to restore colour to every patch. Your preferences, how much the condition affects you and the likelihood of a particular area responding should all be part of the decision. Some people may prefer observation, sun protection or skin camouflage rather than active repigmentation treatment.
Vitiligo can also have a significant psychological and social impact. BAD guidance recommends considering your quality of life and psychological wellbeing, offering self-help information where appropriate and referring for psychological support when distress is moderate or severe.
Why Specialist Assessment Still Matters
Your most appropriate treatment depends on factors including whether your vitiligo is segmental or non-segmental, whether it is stable or progressing, which areas of your body are affected, how extensive it is and which treatments you have previously tried. Your dermatologist should also consider its effect on your quality of life and any relevant autoimmune or medical history.
If you are considering specialist vitiligo treatment in London with an experienced dermatologist, your consultation can help you understand which established or newer treatments may be appropriate and what level of repigmentation is realistic for the areas affecting you.
What Could Future Vitiligo Treatment Look Like?
Researchers continue to investigate additional JAK inhibitors, longer-term treatment strategies and combinations intended to improve the extent or durability of repigmentation. A recently published exploratory phase 2 study found encouraging results when NB-UVB was added to ruxolitinib cream in selected people who had shown limited early improvement.
However, you should not interpret this as an established treatment combination. Current UK product information states that the efficacy and safety of ruxolitinib cream combined with NB-UVB have not yet been established, so no recommendation for routine combined use can currently be made.
Myth vs Fact
| Myth | What You Should Know |
| Modern vitiligo treatment started with corticosteroids. | Vitiligo phototherapy has a much longer history, including earlier psoralen and light-based treatments. |
| Corticosteroids restore colour in everyone. | Your response varies considerably and the original 1976 study showed repigmentation in only some patients. |
| PUVA remains the preferred light treatment. | If phototherapy is appropriate for you in the UK, NB-UVB is generally preferred, while PUVA is reserved for selected adults. |
| Tacrolimus is specifically licensed for vitiligo. | Your dermatologist may use tacrolimus off-label because UK guidance supports it in selected areas such as facial vitiligo. |
| Combination NB-UVB and steroid treatment works for nearly everyone. | The HI-Light trial showed greater success with combination treatment than with topical corticosteroid alone, but only about 27% met the study’s definition of treatment success. |
| Every JAK inhibitor can treat vitiligo. | Ruxolitinib cream is the specifically licensed JAK treatment; other JAK approaches remain under investigation. |
| Ruxolitinib restores facial pigmentation within a few weeks. | Your improvement can be gradual and treatment beyond 24 weeks may be needed. |
| Anyone aged 12 or over with vitiligo can receive NHS ruxolitinib. | Your NHS eligibility requires non-segmental vitiligo with facial involvement and failure or unsuitability of topical first-line treatment. |
| Ruxolitinib plus NB-UVB is now standard treatment. | Research is encouraging, but the combination is not currently established in the UK product information. |
| Successful repigmentation is always permanent. | Your pigmentation can be lost again after treatment stops, so long-term expectations should be discussed with your dermatologist. |
Key Takeaways
- Modern vitiligo treatment developed gradually through advances in topical medicines, phototherapy, targeted light and immune-based treatment.
- If you need first-line treatment, your dermatologist may discuss a potent topical corticosteroid, while tacrolimus may be considered for selected areas such as your face.
- NB-UVB is generally the preferred form of phototherapy in current UK care when topical treatment has not provided an adequate response or your vitiligo is extensive or progressive.
- Combining NB-UVB with topical treatment may improve your chance of a useful response, but repigmentation is not guaranteed and may be lost after treatment stops.
- Ruxolitinib cream targets JAK1 and JAK2 signalling and is licensed for non-segmental vitiligo with facial involvement from age 12.
- In England, NHS access to ruxolitinib is subject to NICE criteria, including failure or unsuitability of topical first-line treatment.
- Your treatment plan should take account of the type, activity and location of your vitiligo, its effect on your quality of life and what matters most to you.
What Does Current UK Guidance Mean for You?
Current UK management still includes established treatments such as potent topical corticosteroids, topical calcineurin inhibitors and NB-UVB according to your type of vitiligo, affected sites and response to previous therapy. Tacrolimus and several other established medicines are used off-label for vitiligo, whereas ruxolitinib cream is specifically licensed for non-segmental vitiligo with facial involvement from age 12.
For NHS use in England, NICE recommends ruxolitinib only when your topical first-line treatments have not worked or are unsuitable. This NHS position is narrower than its marketing authorisation, so being medically eligible under the licence does not automatically mean that you meet the NICE-funded treatment criteria.
Frequently Asked Questions
1. When did modern treatment for vitiligo begin?
Modern vitiligo treatment developed gradually rather than beginning with one single discovery. If you look at the main milestones, psoralen and light therapy came before modern topical corticosteroids, followed by PUVA, NB-UVB, calcineurin inhibitors and more targeted medicines.
2. Do topical corticosteroids still have a role in your vitiligo treatment?
Yes. Current BAD guidance recommends potent or very potent topical corticosteroids as first-line treatment for appropriate vitiligo, although your dermatologist needs to consider the treated site and the risk of local side effects.
3. Why did NB-UVB become more important than PUVA?
If phototherapy is suitable for you, NB-UVB is generally preferred because you do not need to take psoralen before treatment. It has also shown favourable efficacy and colour matching compared with oral PUVA, which is why current UK guidance generally recommends NB-UVB as the preferred phototherapy option.
4. Can a Topical Steroid Be Combined With NB-UVB?
Yes. If combination treatment is suitable for you, your dermatologist may consider using a topical corticosteroid alongside NB-UVB. In the UK HI-Light trial, handheld NB-UVB plus topical corticosteroid was more successful than corticosteroid alone for active, limited vitiligo, although only around one-quarter of participants achieved the trial’s definition of treatment success.
5. Is Tacrolimus Licensed Specifically for Vitiligo?
No. Tacrolimus is used off-label for vitiligo, but BAD guidance recommends considering tacrolimus 0.1% for facial vitiligo and selected other areas as an alternative to potent topical corticosteroids.
6. What is a 308-nm excimer treatment?
If you have localised vitiligo, excimer treatment can direct a focused wavelength of therapeutic light towards selected patches. BAD guidance allows it to be considered for localised disease, although availability through the NHS is limited.
7. How does ruxolitinib work for your vitiligo?
If ruxolitinib is prescribed for you, it works by inhibiting JAK1 and JAK2, which reduces signalling through immune pathways involved in melanocyte destruction. This may allow pigment to return gradually in some areas of your skin, although your response cannot be guaranteed.
8. Who can receive ruxolitinib for vitiligo on the NHS in England?
NICE recommends it for people aged 12 years and over with non-segmental vitiligo involving the face when topical first-line treatments have not worked or are unsuitable.
9. Does ruxolitinib work quickly for everyone?
No. In the phase 3 trials, around 30% of participants receiving ruxolitinib reached at least 75% improvement in facial vitiligo scores by week 24, and some continued improving with longer treatment. Your individual response cannot be predicted or guaranteed.
10. Can you combine ruxolitinib with NB-UVB?
You should not start this combination yourself. Although a recent exploratory study produced encouraging results, current UK product information says that its efficacy and safety with NB-UVB have not been established and no recommendation can currently be made.
Final Thoughts: The Evolution of Vitiligo Treatment
The history of vitiligo treatment shows a gradual shift from broad approaches such as corticosteroids and phototherapy towards treatments informed by a more detailed understanding of autoimmune signalling. NB-UVB, calcineurin inhibitors and, more recently, ruxolitinib have expanded your treatment options, but no approach guarantees complete or permanent repigmentation. If you’re considering vitiligo treatment in London, you can get in touch with us at London Dermatology Centre.
References:
- Eleftheriadou, V., Atkar, R., Batchelor, J., McDonald, B., Novakovic, L., Patel, J.V., Ravenscroft, J., Rush, E., Shah, D., Shah, R., Shaw, L., Thompson, A.R., Hashme, M., Exton, L.S., Mohd Mustapa, M.F. and Manounah, L. (2022) ‘British Association of Dermatologists guidelines for the management of people with vitiligo 2021’, British Journal of Dermatology, 186(1), pp. 18–29. Available at: https://pubmed.ncbi.nlm.nih.gov/34160061/
- Bleehen, S.S. (1976) ‘The treatment of vitiligo with topical corticosteroids. Light and electronmicroscopic studies’, British Journal of Dermatology, 94(Suppl. 12), pp. 43–50. Available at: https://pubmed.ncbi.nlm.nih.gov/773413/
- Seneschal, J., Duplaine, A., Maillard, H., Passeron, T., Andreu, N., Lassalle, R., Favary, C., Droitcourt, C., Taïeb, A. and Ezzedine, K. (2021) ‘Efficacy and safety of tacrolimus 0.1% for the treatment of facial vitiligo: a multicenter randomized, double-blinded, vehicle-controlled study’, Journal of Investigative Dermatology, 141(7), pp. 1728–1734. Available at: https://www.sciencedirect.com/science/article/pii/S0022202X21000774
- Rosmarin, D. et al. (2022) ‘Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo’, The New England Journal of Medicine, 387(16), pp. 1445–1455. Available at: https://pubmed.ncbi.nlm.nih.gov/36260792/
- Diotallevi, F., Gioacchini, H., De Simoni, E., Marani, A., Candelora, M., Paolinelli, M., Molinelli, E., Offidani, A. and Simonetti, O. (2023) ‘Vitiligo, from pathogenesis to therapeutic advances: state of the art’, International Journal of Molecular Sciences, 24(5), article 4910. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10003418/